Roy M, Fowler AM, Ulaner GA, Mahajan A. Molecular classification of breast cancer. PET Clin. 2023;18(4):441–58. https://doi.org/10.1016/j.cpet.2023.04.002.

Article  PubMed  Google Scholar 

Zhang X. Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med. 2023;147(1):46–51. https://doi.org/10.5858/arpa.2022-0070-RA.

Article  PubMed  Google Scholar 

Yu LY, Tang J, Zhang CM, Zeng WJ, Yan H, Li MP, et al. New immunotherapy strategies in breast cancer. Int J Environ Res Public Health. 2017;14(1):68. https://doi.org/10.3390/ijerph14010068.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corraliza-Gorjón I, Somovilla-Crespo B, Santamaria S, Garcia-Sanz JA, Kremer L. New strategies using antibody combinations to increase cancer treatment effectiveness. Front Immunol. 2017;8:1804. https://doi.org/10.3389/fimmu.2017.01804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sivaganesh V, Promi N, Maher S, Peethambaran B. Emerging immunotherapies against novel molecular targets in breast cancer. Int J Mol Sci. 2021;22(5):2433. https://doi.org/10.3390/ijms22052433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14):7517. https://doi.org/10.3390/ijms25147517.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499–511. https://doi.org/10.1016/S1470-2045(20)30754-3.

Article  CAS  PubMed  Google Scholar 

Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–93. https://doi.org/10.1016/j.annonc.2021.05.355.

Article  CAS  PubMed  Google Scholar 

Romero D. KEYNOTE-355 - os benefit now reported. Nat Rev Clin Oncol. 2022;19(10):616. https://doi.org/10.1038/s41571-022-00674-6.

Article  PubMed  Google Scholar 

Zhang H, Jin X, Bian L. Torchlight trial, brightening the life of more patients with advanced triple-negative breast cancer. Transl Breast Cancer Res. 2023;5:1. https://doi.org/10.21037/tbcr-23-33.

Article  PubMed  PubMed Central  Google Scholar 

Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30(9):2528–39. https://doi.org/10.1038/s41591-024-03088-2.

Article  CAS  PubMed  Google Scholar 

Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol. 2023;13:1097983. https://doi.org/10.3389/fonc.2023.1097983.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cardoso F, Hirshfield KM, Kraynyak KA, Tryfonidis K, Bardia A. Immunotherapy for hormone receptor‒positive HER2-negative breast cancer. NPJ Breast Cancer. 2024;10(1):104. https://doi.org/10.1038/s41523-024-00704-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Phillipps J, Zhou AY, Butt OH, Ansstas G. PARP inhibition and immunotherapy: a promising duo in fighting cancer. Transl Cancer Res. 2023;12(9):2433–7. https://doi.org/10.21037/tcr-23-726.

Article  PubMed  PubMed Central  Google Scholar 

Gupta A, Kumar Y. Bispecific antibodies: a novel approach for targeting prominent biomarkers. Hum Vaccin Immunother. 2020;16(11):2831–9. https://doi.org/10.1080/21645515.2020.1738167.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cooke HA, Arndt J, Quan C, Shapiro RI, Wen D, Foley S, et al. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies. MAbs. 2018;10(8):1248–59. https://doi.org/10.1080/19420862.2018.1519631.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7. https://doi.org/10.1038/s41523-023-00508-3.

Article  PubMed  PubMed Central  Google Scholar 

Goebeler ME, Bargou RC. T cell-engaging therapies—BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–34. https://doi.org/10.1038/s41571-020-0347-5.

Article  PubMed  Google Scholar 

Lantz J, Pham N, Jones C, Reed D, El Chaer F, Keng M. Blinatumomab in practice. Curr Hematol Malig Rep. 2024;19(1):1–8. https://doi.org/10.1007/s11899-023-00714-7.

Article  PubMed  Google Scholar 

Nix MA, Lareau CA, Verboon J, Kugler DG. Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. Front Immunol. 2024;15:1492782. https://doi.org/10.3389/fimmu.2024.1492782.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eini M, Zainodini N, Montazeri H, Mirzabeigi P, Tarighi P. A review of therapeutic antibodies in breast cancer. J Pharm Pharm Sci. 2021;24:363–80. https://doi.org/10.18433/jpps31864.

Article  CAS  PubMed  Google Scholar 

Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12):e005543. https://doi.org/10.1136/jitc-2022-005543.

Article  PubMed  PubMed Central  Google Scholar 

Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008;17(10):1553–8. https://doi.org/10.1517/13543784.17.10.1553.

Article  CAS  PubMed  Google Scholar 

Tebotelimab is safe and effective across multiple cancer types. Cancer Discov. 2024;14(1):OF4. https://doi.org/10.1158/2159-8290.CD-RW2023-174.

Pusztai L, Denkert C, O’Shaughnessy J, Cortes J, Dent R, McArthur H, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024;35(5):429–36. https://doi.org/10.1016/j.annonc.2024.02.002.

Article  CAS  PubMed  Google Scholar 

Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, et al. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006;12(2):569–76. https://doi.org/10.1158/1078-0432.CCR-05-2005.

Article  CAS  PubMed  Google Scholar 

Lum LG, Al-Kadhimi Z, Deol A, et al. Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. J Immunother Cancer. 2021;9(6):e002194. https://doi.org/10.1136/jitc-2020-00219.

Article  PubMed  PubMed Central